Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010
The risk of hepatotoxicity of anti-tuberculosis drugs in patients from regions with high prevalence of hepatitis B Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007
Can toxicities induced by antituberculosis drugs be better managed in diabetic patients? Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017 Year: 2017
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005
The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002
Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
Reasons for hepatotoxic reactions to chemotherapeutic agents and possibilities of their prevention in adolescents with tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001
The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007
Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005
Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Source: Eur Respir J 2006; 28: Suppl. 50, 128s Year: 2006
Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019
Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008